InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
MrTrader129 Free
07/10/25 12:18 PM
profile icon
BigBadWolf PremiumMember
07/08/25 11:05 AM
profile icon
HIFI Free
07/07/25 1:40 PM
profile icon
BigBadWolf PremiumMember
07/03/25 4:23 PM
profile icon
BigBadWolf PremiumMember
07/01/25 8:41 AM
profile icon
MrTrader129 Free
07/01/25 12:56 AM
profile icon
tractor4sale Free
06/30/25 5:28 PM
profile icon
johnnytrader33 Free
06/30/25 10:32 AM
profile icon
BigBadWolf PremiumMember
06/30/25 10:01 AM
profile icon
BigBadWolf PremiumMember
06/30/25 9:59 AM
profile icon
sundoctor Free
06/30/25 8:45 AM
Bullish
Bullish
profile icon
Yooperman Free
06/27/25 1:55 PM
profile icon
MrTrader129 Free
06/25/25 11:55 AM
profile icon
MrTrader129 Free
06/24/25 10:59 AM
profile icon
BigBadWolf PremiumMember
06/23/25 3:57 PM
profile icon
HIFI Free
06/23/25 11:33 AM
profile icon
Lime Time Free
06/23/25 10:34 AM
Bullish
Bullish
profile icon
sundoctor Free
06/23/25 10:23 AM
Bullish
Bullish
profile icon
BigBadWolf PremiumMember
06/17/25 9:37 AM
profile icon
work-n-hard Free
06/16/25 5:35 PM
profile icon
BigBadWolf PremiumMember
06/14/25 9:50 AM
profile icon
Homebrew PremiumMember
06/14/25 9:26 AM
profile icon
tractor4sale Free
06/14/25 7:25 AM
profile icon
Homebrew PremiumMember
06/13/25 11:01 PM
profile icon
Homebrew PremiumMember
06/13/25 4:36 PM
profile icon
tractor4sale Free
06/13/25 4:26 PM
profile icon
Homebrew PremiumMember
06/13/25 3:43 PM
profile icon
tractor4sale Free
06/13/25 3:01 PM
profile icon
Homebrew PremiumMember
06/13/25 2:50 PM
profile icon
BigBadWolf PremiumMember
06/13/25 1:20 PM
profile icon
tractor4sale Free
06/13/25 12:39 PM
profile icon
Homebrew PremiumMember
06/12/25 7:58 PM
profile icon
Homebrew PremiumMember
06/12/25 7:55 PM
profile icon
BigBadWolf PremiumMember
06/09/25 10:12 AM
profile icon
sundoctor Free
06/09/25 9:42 AM
Bullish
Bullish
profile icon
tractor4sale Free
06/09/25 6:39 AM
profile icon
xstream Free
06/08/25 9:04 AM
profile icon
sundoctor Free
06/05/25 10:08 AM
Bullish
Bullish
profile icon
BigBadWolf PremiumMember
06/04/25 7:12 PM

Therapeutic Solutions International Inc (TSOI) RSS Feed

Followers
517
Posters
Posts (Today)
0
Posts (Total)
66889
Created
10/04/08
Type
Free
Moderators BigBadWolf johnnytrader33 JMC$ Yooperman Hogwarts
---------------------------------nothing can be posted above only @ the bottom as per Ihub Rules this section maintained by BBW--------------------------------------------------------
Therapeutic Solutions International Inc (TSOI)
COMPANY OFFICERS & CONTACTS
Timothy G. Dixon
President, CEO
 
BOARD OF DIRECTORS
Timothy G. Dixon President, CEO
Thomas E. Ichim, Ph.D 
 
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report 01/07/2025 8K Report
CIK 0001419051
Fiscal Year End 12/31
 
Accounting/Auditing Firm
Fruci & Associates II, PLLC
802 N. Washington St.
Spokane, WA 99201

 
Securities Counsel 
H. D. Kelso and Associates
8799 Balboa Ave
San Diego, CA 92123
Security Details w/ all the increases will be found @ the bottom  dating from 2021 to present.  

Along w/ Dixon/Ichim/TSOI quotes, screenshots to collaberate & document the below concerns, while also including those captured after the initiating of the 2025 delisting process.

Now if any shareholders past or present believe that Timothy G. Dixon (CEO of TSOI) has been:
Harassing or threatening shareholders,

Conditioning dividends on disclosure of personal information,

Transferring shareholder assets to privately held subsidiaries under his control,

Using lawsuits to intimidate critics,

as these are not only ethically troubling but may also violate SEC regulations, state corporate laws, and potentially civil or criminal statutes depending on the specifics.

What You Can Do: 
1. Document Everything
Keep records of all communications, threats, filings, and any demands for personal information.

2. Report to Regulators: A legal draft of said for any (to be filled out) will be found @ the end of this section.
You or affected shareholders can file complaints with:

SEC Office of Investor Education and Advocacy

FINRA (if a broker-dealer is involved)

Your state securities regulator (NASAA directory)

3. Contact an Attorney
This situation may warrant:

A class-action suit if many shareholders have been affected similarly.

An injunction if the company is coercing shareholders under false pretenses.

Legal defenses for shareholders who are being sued or doxxed.

4. Go Public
Consider engaging with:

Investor rights groups

Financial journalists

OTC Markets  

Final Thoughts After a Legal Review of the Aforementioned Shareholder Concerns.
This kind of behavior, if verified, is not typical corporate conduct and is not protected under the umbrella of "business judgment." The CEO of a public company has fiduciary obligations to shareholders and cannot retaliate against dissent or misuse shareholder data or assets.

Supporting Documentation to be included will be found @ the bottom of the Submission Draft.
Draft of Submission Below
[Your Name or Investor Group Name]

[Your Address]
[Your Email or Phone Number]
Date
To:

U.S. Securities and Exchange Commission (SEC)

FINRA (Financial Industry Regulatory Authority)

OTC Markets

State Securities Regulator (if applicable)

Subject: Formal Complaint Regarding Alleged Fraud, Harassment, and Misuse of Shareholder Assets by Timothy G. Dixon (TSOI)

I. Introduction
We, the concerned shareholders of Therapeutic Solutions International Inc. (TSOI), wish to file a formal complaint regarding the actions of Timothy G. Dixon, the CEO of TSOI. For several years, Mr. Dixon has been alleged to engage in fraudulent practices, harassment of shareholders, and misuse of company assets for personal gain. These actions have resulted in significant harm to the shareholders of TSOI and may constitute violations of both securities law and ethical corporate governance.

II. Allegations of Fraud, Harassment, and Shareholder Exploitation
Harassment and Coercion of Shareholders:

Mr. Dixon has been alleged to harass shareholders who have expressed dissatisfaction with company operations or who have criticized his leadership.

Shareholders have reported threatening behavior and intimidation tactics, including direct and indirect threats of legal action and exclusion from corporate benefits if shareholders do not comply with his demands.

Misuse of Shareholder Personal Information:

In an unusual “loyalty dividend” program, Mr. Dixon required TSOI shareholders to provide detailed personal information, including brokerage account statements in exchange for shares in a subsidiary, Breathe Biologics, Inc. (BRTH).

Shareholders were told that they would not receive the dividend unless they provided their personal and financial details directly to Mr. Dixon or to his private company. This has raised privacy concerns and the possibility of identity theft or data misuse.

Asset Transfers to Privately Controlled Entities:

Mr. Dixon has transferred TSOI shareholder assets to BRTH, a privately controlled entity. Shareholders of TSOI were not given the opportunity to vote on these transfers, nor were they compensated or adequately informed about the nature of the transactions.

It is believed that Mr. Dixon is attempting to privatize TSOI’s assets and has given preferential treatment to himself and his associates.

Legal Actions Against Shareholder Critics:

In addition to harassing individual shareholders, Mr. Dixon has initiated lawsuits to identify anonymous critics posting on online forums (e.g., Stocktwits).

These lawsuits appear to be an effort to silence dissent and intimidate shareholders who have raised concerns about the company’s management and practices.

Threats and Intimidation Toward Shareholders Who Disagree:

Shareholders who refuse to comply with Mr. Dixon's demands (e.g., submission of personal information or silence regarding corporate mismanagement) have been threatened with legal actions, loss of access to dividends, or being excluded from future shareholder opportunities.

III. Requested Actions
We respectfully request the following actions:

Investigation of TSOI’s corporate governance practices and an examination of Timothy G. Dixon’s conduct, particularly regarding harassment of shareholders, misuse of shareholder assets, and possible fraudulent transfers of company property.

Review of Mr. Dixon’s handling of the "loyalty dividend" program to ensure that shareholder personal information has been handled legally and securely.

Examination of the legal actions initiated by Mr. Dixon to identify and harass anonymous critics of the company, and a determination of whether these actions are a violation of shareholder rights and freedoms.

Investigation into the legitimacy of the transition from TSOI to BRTH, ensuring that all transactions and asset transfers are transparent, fair, and legal.


IV. Conclusion
The actions of Timothy G. Dixon and TSOI raise significant concerns about the company’s operations and its treatment of shareholders. We urge the appropriate authorities to conduct a thorough investigation into these allegations and take appropriate action to protect the rights of TSOI’s shareholders.

We have included copies of relevant communications, filings, and testimonies from shareholders to support this complaint. We are happy to provide any additional information or documentation required for your investigation.

Sincerely,
[Your Name / Shareholder Group Name]

[Contact Information]

Next Steps:
Send this letter to the SEC, FINRA, OTC Markets, and your state securities regulator.

Consider attaching evidence, such as copies of emails, filings, and links to posts or communications that support the claims.

Reach out to a securities attorney to discuss the possibility of legal action, especially if you are a shareholder who has been harmed by these practices.





























































































































































































































FDA Health News


NEWS 12/31/20 Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company

Campbell Neurosciences to License Key Intellectual Property Assets as Clinical Trials of Campbell Score and Kaihani Score are Ongoing

OCEANSIDE, Calif., Dec. 31, 2020 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the launching of Campbell Neurosciences Inc as a partially owned spin-off from the Company. The new corporation will be led by Ms. Kalina O'Connor as President and Chief Executive Officer, Dr. James Veltmeyer as Chief Medical Officer, and Ms. Jona Barnes as Chief Financial Officer.

Campbell Neurosciences Inc has signed license agreements with Therapeutic Solutions International for access to the 9 patents filed related to the previous Campbell Neurosciences Division. The patents are:

1. 63/128759 Immunotherapy for Opioid Addiction
2. 63/122862 Treatment of Major Depressive Disorder and Suicidal Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing Plant-Based Approaches
3. 63/105964 Protection/Regeneration of Neurological Function by Endothelial Protection/Rejuvenation using Stem Cells for Treatment of Conditions such as Chronic Traumatic Encephalopathy and Schizophrenia
4. 17/030416 Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention
5. 63/077723 Immunotherapy of Schizophrenia and Schizophrenia Associated Suicidal Ideation/Suicide
6. 63/071381 Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline
7. 63/068388 Methods of Determining Risk of Suicide and/or Suicidal Ideation by Immunological Assessment
8. 63/061202 Prevention of Neuroinflammation associated Memory Loss Using Nutraceutical Compositions
9. 63/057315 Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof

Additionally, Campbell Neurosciences Inc. has entered into purchase agreements with Therapeutic Solutions International ensuring a continued supply, at a discounted rate, of nutraceuticals which are being explored for antiinflammation/suicide prevention activity.

"I am honored that the Board of Therapeutic Solutions International has agreed to spin off the Campbell Neurosciences Division as an independent entity," said Kalina O'Connor, Chief Executive Officer of Campbell Neurosciences Inc. "By leveraging the unique relationship between immunology, neurosciences and regenerative medicine, we aim to position ourselves as leaders in establishing a scientific and quantifiable basis to the practice of regenerative psychiatry."

"Having collaborated with Ms. O'Connor in our work at Therapeutic Solutions International, I am pleased to be the Chief Medical Officer of Campbell Neurosciences, a company dedicated to preventing suicide," said Dr. James Veltmeyer. "We are dedicated to demonstrating to the world that suicide is not a choice but a disease."

"Ms. O'Connor approached us with the idea of forming a company named after her mother, Kathleen Campbell, who was a victim of suicide. I was impressed by Ms. O'Connor's deep insight into biology, as well as her unwavering commitment to help other people in her mother's situation," said Timothy Dixon, Chairman, President and CEO of Therapeutic Solutions International. "Having worked with Ms. O'Connor and after meeting certain milestones including establishment of two clinical trials, the board decided that enhanced value can be obtained with Campbell Neurosciences spinning out as a separate entity. We will support Ms. O'Connor and Campbell Neurosciences on an ongoing basis."



NEWS 12/30/20 Therapeutic Solutions International Reports QuadraMune™ Increases T Cell Immunity in Animal Studies

Accumulating Data Supports Possibility of Enhanced Antiviral Immunity Using Nutraceutical Approach

OCEANSIDE, Calif., Dec. 30, 2020 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data demonstrating a two-week course of QuadraMune™ increased immunological parameters relevant to antiviral immunity.

In a series of experiments, the Company demonstrated that animals injected with a model antigen, keyhole limpet hemacyanin (KLH) possessed a significantly enhanced T cell response. The type of T cell response that was preferentially elicited in animals taking QuadraMune was associated with interferon gamma, a protein known to inhibit viral replication.

"Previously we have demonstrated that QuadraMune is associated with enhanced natural killer cells, which represent the innate arm of the immune system" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The demonstration that the adaptive immune response is also enhanced by QuadraMune, provides further rationale for evaluation of this nutraceutical as a preventative for COVID-19."

The Company is currently running a clinical trial in health care workers using QuadraMune to prevent COVID-19 infection. More information on the clinical trial can be found on the Federal Clinical Trials registry as #NCT04421391.

"Although there are numerous nutraceutical products on the market that claim to boost immunity, I am extremely proud that we as a company are differentiating ourselves by conducting scientific experiments to objectively validate our approach" said Famela Ramos, Vice President of Business Development.

"Our Company is based on utilizing the immune system to treat numerous chronic and degenerative conditions. Today's findings, that QuadraMune stimulates the Th1 arm of the immune system, suggests that QuadraMune may be useful for other conditions associated with immune dysregulation" said Timothy Dixon, President and CEO of the Company. "It is believed that Th1 immunity is useful not only in the treatment of viruses but also in eradication of cancer and intracellular bacterial." NEWS 12/21/20
Therapeutic Solutions International Files Patent on NeuroLeukin™ Personalized Immunotherapy for Opioid Addiction

Campbell Neurosciences Division Expands its "Regenerative Psychiatry" Approach to Address the $179 Billion Dollar Prescription Opioid Epidemic


OCEANSIDE, Calif., Dec. 21, 2020 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today novel data and filing of a patent covering utilization of its NeuroLeukin™ product for altering molecular pathways associated with opioid addiction. In a series of animal experiments NeuroLeukin™ was demonstrated to reduce activation of TLR-4, which is one of the major innate immune pathways associated with opioid tolerance and addiction1.

It is estimated that the current opioid use epidemic costs the health care system approximately $179 Billion annually2. Campbell Neurosciences, the Company's Division focused on suicide prevention has previously filed intellectual property on utilizing NeuroLeukin™ to reduce suicidal ideations.

"The common biochemical pathways of opioid addiction and suicidal ideation should be no surprise given the inherent relationship between these two conditions," said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of the patent. "Currently we have 2 clinical trials on the Federal ClinicalTrials.gov website dealing with immunological quantification of psychiatric disorders: suicide and gambling. We are excited to take NeuroLeukin™ into the clinic, which to my knowledge represents the first immunotherapeutic approach for opioid addiction."

"Immunotherapy, which at one point was considered on the fringe of medicine, has blossomed into what is expected to be a 126-billion-dollar annual market in 20263, given its recent successes in the treatment of cancer," said Famela Ramos, Vice President of Business Development and co-inventor of the patent. "We are excited to position ourselves as the potential leaders in applying immunotherapy to mental disorders, an approach that we like to call "regenerative psychiatry."

"Having seen many close friends of mine suffer the horrible effects of opioid addiction, I am proud to be co-inventor on an approach which has the potential to revolutionize the way drug addiction is seen by the medical community," said Wais Kaihani, consultant to the Company.

"I am thankful for our internationally renowned scientific advisory board, which is comprised of immunologists and neurobiologists, that have stimulated our Company to enter such an unexplored space in which very little therapeutic interventions exist," said Timothy Dixon, President and CEO of the Company and co-inventor. "We are 100% dedicated to ending the opioid crisis or catalyzing development of novel approaches to accelerate an end to this tragic and avoidable loss of life."

1 Discovery of a Novel Site of Opioid Action at the Innate Immune Pattern-Recognition Receptor TLR4 and its Role in Addiction - ScienceDirect
2 What Are The Real Costs Of The Opioid Epidemic? : Shots - Health News : NPR
3 Cancer Immunotherapy Market Worth $126.9 Billion By 2026 (grandviewresearch.com)




NEWS 12/17/20
Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell


OCEANSIDE, Calif., Dec. 17, 2020 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of an Investigational New Drug (IND) application seeking permission from the Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial assessing safety and signals of efficacy for treatment of Chronic Traumatic Encephalopathy (CTE) patients with JadiCells™.

The JadiCell is a type of umbilical cord derived mesenchymal stem cell which possesses superior therapeutic activity as compared to other stem cell types based on laboratory and clinical studies. The JadiCell was recently reported to possess therapeutic activity against COVID-19 in a recently published clinical trial1. The Company previously obtained an exclusive license for use of JadiCells for CTE and Traumatic Brain Injury (TBI)2,3.

"My team and myself are extremely excited about the potential of using our unique novel cell therapy for treatment of CTE, which is the cause of countless deaths, as well as chronic disabilities" said Dr. Amit Patel, inventor of the JadiCell. "Having worked over the past several years with the multidisciplinary team assembled by Timothy Dixon, I look forward to progress in this area of medicine, for which currently there are limited options."

Chronic Traumatic Encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players4. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia. In many patients with CTE, it is anatomically characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe. TSOI has previously filed several patents in the area of CTE based on modulating the brain microenvironment to enhance receptivity of regenerative cells such as stem cells.

Suicide is a major cause of death in military veterans, approximately 20 deaths per day5. It is widely known that TBI and CTE are associated with increased propensity for suicide6,7. Furthermore, studies show that cytokines associated with brain inflammation, such as IL-6 and TNF-alpha are found in higher levels in patients with suicidal tendencies8.

"To our knowledge, this is the first therapeutic intervention addressing CTE using stem cells and we are tremendously excited to finally move into clinical testing for this terrible disease that not only affects athletes but our military and law enforcement as well" said Timothy Dixon, President and CEO of the Company. "Having worked over the last 2 years in developing the preclinical data supporting this IND, we are extremely pleased to file this new drug application today."


1 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875

2 https://www.globenewswire.com/news-release/2019/07/01/1876699/0/en/Therapeutic-Solutions-International-2Obtains-Exclusive-License-for-Patented-Clinical-Stage-Adult-Stem-Cell-for-Treatment-of-Military-and-Sports-Brain-Injuries.html

3 https://patents.google.com/patent/US9803176?oq=9803176

4 https://www.nytimes.com/interactive/2017/07/25/sports/football/nfl-cte.html

5 https://en.wikipedia.org/wiki/United_States_military_veteran_suicide

6 https://www.psychcongress.com/news/traumatic-brain-injury-tied-increased-risk-suicide

7 https://sbindependent.org/nfl-athletes-with-cte-who-committed-suicide/

8 https://www.ncbi.nlm.nih.gov/pubmed/20951793




NEWS 12/16/20
Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention
Campbell Neurosciences Division Aims to Combat Suicide-Causing Brain Inflammation using Stromal Vascular Fraction Immunotherapy



OCEANSIDE, Calif., Dec. 16, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today signing a letter of intent with Synova Life Sciences aimed at developing a "First in Class" cellular therapy for suicide and suicidal ideation.

Under the proposed collaboration, Therapeutic Solutions International will contribute its existing expertise and intellectual property regarding adipose stem cell treatment of neuroinflammatory disorders, whereas Synova Life Sciences will provide access to its non-enzymatic stromal vascular fraction isolation device.

The two parties aim to file an Investigational New Drug (IND) application to the FDA for initiating a clinical trial in patients at high risk of suicide.

"Numerous publications have supported potent anti-inflammatory activity of stromal vascular fraction (SVF) cells 1, 2, which are rich not only in mesenchymal stem cells, but also in T regulatory cells, type 2 monocytes, and endothelial progenitor cells3," said Kalina O'Connor, Director of the Company's Campbell Neurosciences, which is focused on Suicide Prevention. "We are highly impressed by the superior speed, viability, and quality of SVF cells obtained using the Synova Life Sciences device as compared to other collagenase-based approaches. Based on this, we are eager to initiate collaborations in leveraging this device to extract the cellular fractions which we hope will be useful in reducing suicidal ideations and suicide."

"I look forward at working with the Team at Therapeutic Solutions International in advancing this novel utility of adipose derived stem cells," said John Chi, President and CEO of Synova Life Sciences. "Through collaboration with cutting edge innovators, we believe we will obtain greatest shareholder value while accelerating the progress of medicine."

"To our knowledge the Synova Device not only provides the highest quality cells, but also accomplishes this is in more rapid time than compared to other devices," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "The rapid development and track record of success possessed by the team at Synova, makes them ideal partners for us as we enter this brave new world of regenerative psychiatry."



1 Bowels et al. Immunomodulatory Effects of Adipose Stromal Vascular Fraction Cells Promote Alternative Activation Macrophages to Repair Tissue Damage. Stem Cells. 2017 Oct;35(10):2198-2207.
2 Riordan et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med. 2009 Apr 24;7:29.
3 Mizer et al. Exogenous endothelial cells as accelerators of hematopoietic reconstitution. J Transl Med . 2012 Nov 21;10:231.



NEWS 12/9/20
Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder

Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
 

OCEANSIDE, Calif., Dec. 9, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.

The experiments, which involved exposing mice to established stressors, demonstrated that specific areas of the brain associated with production of new brain cells are damaged by stress.  In agreement with previously published research, administration of fluoxetine (Prozac™) protected the brain from stress-induced damage.  Surprisingly, QuadraMune™ administration appeared superior to Prozac™ at stimulating proliferation of new brain cells. 

"QuadraMune™ which is currently in a clinical trial for prevention of COVD-191, has also been demonstrated to possess anti-inflammatory activity in other clinical trials, suppressing cytokines such as IL-62, which are known to be involved in depression3 and suicide4" said Kalina O'Connor, Director of Campbell Neurosciences and co-inventor on the patent.  "Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune™ for preventing suicide."

"Although much enthusiasm has been generated over the planned distribution of the COVID vaccine, at present little is being done to address mental health issues that are being exacerbated by the current pandemic" said Dr. James Veltmeyer, co-inventor of the patent, and Chief Medical Officer of the Company. "If current results are reproducible, the possibility that a nutraceutical would concurrently boost immunity while preserving mental health is highly enticing."

"It has not escaped us that COVID-19 is associated with increased inflammatory cytokines in the blood of patients, cytokines that also predispose to depression" said Famela Ramos, Vice President of Business Development for the Company. "It may be that the recent increase in suicides and suicide attempts is related biologically to activities of the coronavirus. It will be interesting to examine whether QuadraMune™ may modify putative negative mental effects of the virus."

"An estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all U.S. adults" stated Timothy Dixon, President and CEO of the Company. "We believe the Mission of our Company is not just providing a return on investment to our shareholders, but also increasing the quality of life for Americans.  We are extremely pleased to report this unexpected finding with significant potential implications to advancing non-toxic means of helping patients with this terrible condition."

1 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19 | BioSpace
3 Ting et al. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194.
4 O'Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.



“Stem Cell Therapy ; Authorizes allopathic physicians & osteopathic physicians to perform stem cell therapy not approved by United States Food & Drug Administration; …”


Allopathic physicians – These are MDs (Doctors of Medicine). They practice what is often considered conventional or "Western" medicine, using drugs, radiation, or surgery to treat disease.

Osteopathic physicians – These are DOs (Doctors of Osteopathic Medicine). They are also fully licensed doctors like MDs but receive additional training in the musculoskeletal system and may use hands-on techniques like osteopathic manipulative treatment (OMT).

The aforementioned quoted statement means that both MDs and DOs would be allowed to perform certain stem cell therapies that haven't yet been approved by the FDA, if this proposal or law is enacted.


Dixon it appears thinks the above is a positive as per Dixon & TSOI's FB page





Authorized Shares 9,000,000,000 05/22/2025
Outstanding Shares 6,922,487,587 05/22/2025 >549.500,000
Restricted 2,231,786,481 05/22/2025 >549,500,000
Unrestricted 4,690,701,106 05/22/2025
Held at DTC 4,641,186,779 05/22/2025

Authorized Shares 9,000,000,000 04/14/2025
Outstanding Shares 6,372,987,587 04/14/2025
Restricted 1,682,286,481 04/14/2025
Unrestricted 4,690,701,106 04/14/2025
Held at DTC 4,641,186,779 04/14/2025


Authorized Shares 9,000,000,000 03/25/2025
Outstanding Shares 6,372,987,587 03/25/2025
Restricted 1,682,286,481 03/25/2025
Unrestricted 4,690,701,106 03/25/2025
Held at DTC 4,641,186,779 03/25/2025

Authorized Shares 9,000,000,000 03/04/2025
Outstanding Shares 6,372,987,587 03/04/2025 >480,794,871
Restricted 1,682,286,481 03/04/2025 >33,333,333
Unrestricted 4,690,701,106 3/04/2025 >447,461,538
Held at DTC 4,424,494,471 03/04/2025 >230,769,230

Authorized Shares 9,000,000,000 02/19/2025
Outstanding Shares 5,892,192,716 02/19/2025
Restricted 1,648,953,148 02/19/2025
Unrestricted 4,243,239,568 02/19/2025
Held at DTC 4,193,725,241 02/19/2025

Authorized Shares 9,000,000,000 01/29/2025
Outstanding Shares 5,799,885,024 01/29/2025
Restricted 1,648,953,148 01/29/2025
Unrestricted 4,150,931,876 01/29/2025
Held at DTC 4,101,417,549 01/29/2025

I'll let all do the math Authorized Shares 9,000,000,000 01/15/2025
Outstanding Shares 5,799,885,024 01/15/2025
Restricted 1,648,953,148 01/15/2025
Unrestricted 4,150,931,876 01/15/2025
Held at DTC 4,101,417,549 01/15/2025

I’ll let all do the math frown Authorized Shares 6,500,000,000 12/30/2024
Outstanding Shares 5,705,269,639 12/30/2024
Restricted 1,648,953,148 12/30/2024
Unrestricted 4,056,316,491 12/30/2024
Held at DTC 3,881,802,164 12/30/2024

Authorized Shares 6,500,000,000 11/29/2024
Outstanding Shares 5,255,269,639 11/29/2024 >132,564,103
Restricted 1,648,953,148 11/29/2024
Unrestricted 3,606,316,491 11/29/2024 >182,078,430
Held at DTC 3,556,802,164 11/29/2024 >132,564,103

Authorized Shares 6,500,000,000 11/19/2024
Outstanding Shares 5,122,705,536 11/19/2024
Restricted 1,648,953,148 11/19/2024
Unrestricted 3,473,752,388 11/19/2024
Held at DTC 3,424,238,061 11/19/2024
As of November 20, 2024, 5,122,705,536 shares of the registrant’s common stock, par value of $0.001 per shares, were outstanding

Updated SS Authorized Shares 6,500,000,000 11/04/2024
Outstanding Shares 5,122,705,536 11/04/2024
Restricted 1,649,049,648M11/04/2024 >96,500
Unrestricted 3,473,655,888 11/04/2024
Held at DTC 3,424,238,061 11/04/2024 <96,500

Authorized Shares 6,500,000,000 10/03/2024
Outstanding Shares 5,122,705,536n10/03/2024
Restrictedn1,648,953,148 10/03/2024
Unrestricted 3,473,752,388 10/03/2024
Held at DTC 3,424,334,561 10/03/2024

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175130129&txt2find=Share
Authorized Shares 6,500,000,000 08/20/2024
Outstanding Shares 5,057,149,981 08/20/2024 >173,054,706
Restricted 1,603,397,593 08/20/2024
Unrestricted 3,453,752,388 08/20/2024
Held at DTC 3,231,279,855 08/20/2024
As of August 19, 2024, 4,884,095,275 shares of the registrant’s common stock, par value of $0.001 per shares, were outstanding.

…always loved possible coincidences of wonder why’s & mathematics
https://www.otcmarkets.com/filing/html?id=17873088&guid=pLL-keKdSJI-B3h

https://www.otcmarkets.com/filing/html?id=17873091&guid=pLL-keKdSJI-B3h
 
Outstanding Shares 4,815,913,457 07/26/2024

As of August 19, 2024, 4,884,095,275 shares of the registrant’s common stock, par value of $0.001 per shares, were outstanding.


https://www.otcmarkets.com/filing/html?id=17772050&guid=AvO-k6ImV7-FJth

Authorized Shares ,500,000,000 07/09/2024
Outstanding Shares 4,772,580,124 07/09/2024 >113,562,500 Discount'em Dixon
Restricted 1,559,064,260 07/09/2024 >36,970,000
Unrestricted 3,213,515,864 07/09/2024 >76,562,500
Held at DTC 3,086,505,537 07/09/2024

$TSOI >SS again 67,500,000 in 24 days
Authorized Shares 6,500,000,000 06/24/2024
Outstanding Shares 4,659,017,624 06/24/2024 >20,000,000
Restricted 1,522,064,260 06/24/2024 >20,000,000
Unrestricted 3,136,953,364 06/24/2024
Held at DTC 3,086,505,537 06/24/2024
Again T/A Verifies $Dixon is responsible for $TSOI's $Ongoing decreasing pps over the years


>SS Authorized Shares 6,500,000,000 06/12/2024
Outstanding Shares 4,639,017,624 06/12/2024 >47,500,000
Restricted 1,502,064,260 06/12/2024 >47,500,000
Unrestricted 3,136,953,364 06/12/2024
Held at DTC 3,086,505,537 06/12/2024

Authorized Shares 6,500,000,000 05/30/2024
Outstanding Shares 4,591,517,624 05/30/2024
Restricted 1,454,564,260 05/30/2024
Unrestricted 3,136,953,364 05/30/2024
Held at DTC 3,086,505,537 05/30/2024

Authorized Shares 6,500,000,000 05/30/2024
Outstanding Shares 4,591,517,624 05/30/2024
Restricted 1,454,564,260 05/30/2024
Unrestricted 3,136,953,364 05/30/2024
Held at DTC 3,086,505,537 05/30/2024

https://www.otcmarkets.com/filing/html?id=17584417&guid=QxQ-k6AKM5_WJth

Authorized Shares 6,500,000,000 05/14/2024
Outstanding Shares 4,591,517,624 05/14/2024 >195,138,889
Restricted 1,454,564,260 05/14/2024
Unrestricted 3,136,953,364 05/14/2024 >195,138,889
Held at DTC 3,086,505,537 05/14/2024 >246,725,431 aka true float

Authorized Shares 6,500,000,000 04/22/2024
Outstanding Shares 4,396,378,735 04/22/2024 >166,261,866
Restricted 1,454,564,260 04/22/2024 >57,857,142
Unrestricted 2,941,814,475 04/22/2024 >108,404,724
Held at DTC 2,839,780,106 04/22/2024 >56,818,182
T/A verifies Tim Dixon is responsible for the Ongoing pps decline

Authorized Shares 6,500,000,000 04/15/2024
Outstanding Shares 4,230,116,869 04/15/2024
Restricted 1,396,707,118 04/15/2024
Unrestricted 2,833,409,751 04/15/2024
Held at DTC 2,782,961,924 04/15/2024

Authorized Shares 6,500,000,000 04/03/2024

Outstanding Shares 4,230,116,869 04/03/2024
Restricted 1,396,707,118 04/03/2024
Unrestricted 2,833,409,751 04/03/2024
Held at DTC 2,782,961,924 04/03/2024

Authorized Shares 6,500,000,000 03/18/2024
Outstanding Shares 4,153,512,083 03/18/2024
Restricted 1,386,707,118 03/18/2024
Unrestricted 2,766,804,965 03/18/2024
Held at DTC 2,716,357,138 03/18/2024

Updated SS Increases Authorized Shares 6,500,000,000 02/27/2024
Outstanding Shares 4,054,204,583 02/27/2024 >195,340,422
Restricted 1,366,707,118 02/27/2024 >41,000,000
Unrestricted 2,687,497,465 02/27/2024 >154,340,422
Held at DTC 2,637,049,638 02/27/2024 >154,340,422
Timothy G. Dixon Solely Responsible as the CEO’s signature attest to
discounted dilution
Right on Cue Authorized Shares 5,500,000,000 02/06/2024
Outstanding Shares 3,858,864,161 02/06/2024 >56,197,188
Restricted 1,325,707,118 02/06/2024
Unrestricted 2,533,157,043 02/06/2024 >56,197,183
Held at DTC 2,482,709,216 02/06/2024 >56,197,183

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173935237

Right on Cue
 Authorized Shares 5,500,000,000 02/06/2024
Outstanding Shares 3,858,864,161 02/06/2024 >56,197,188
Restricted 1,325,707,118 02/06/2024
Unrestricted 2,533,157,043 02/06/2024 >56,197,183
Held at DTC 2,482,709,216 02/06/2024 >56,197,183

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

The securities Purchase Agreement (section 1(u)) also contains a provision for a discount rate different from above in the event we were to uplist to a National Exchange, as that meaning is defined in the Act. The Company has no plans to uplist in the foreseeable future, if ever.

 

The Common Stock is quoted on the OTC Markets, under the symbol “TSOI.” On January 30, 2024, the last reported sale price of the Common Stock on the OTC Markets was $0.00105 per share


https://www.otcmarkets.com/filing/html?id=17237897&guid=lAd-kpF5cwRSJth

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173785145

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173783154

Authorized Shares 5,500,000,000 01/18/2024
Outstanding Shares 3,802,666,978 01/18/2024
Restricted 1,325,707,118 01/18/2024
Unrestricted 2,476,959,860 01/18/2024
Held at DTC 2,426,512,033 01/18/2024

Authorized Shares 5,500,000,000 01/08/2024
Outstanding Shares 3,802,666,978 01/08/2024
Restricted 1,325,707,118 01/08/2024
Unrestricted 2,476,959,860 01/08/2024
Held at DTC 2,426,512,033 01/08/2024

Authorized Shares 5,500,000,000 12/12/2023

Outstanding Shares 3,802,666,978 12/12/2023 >66,217,554
Restricted 1,325,707,118 12/12/2023
Unrestricted 2,476,959,860 12/12/2023 >66,217,554
Held at DTC 2,426,512,033 12/12/2023 >66,217,554

Authorized Shares 5,500,000,000 11/28/2023
Outstanding Shares 3,736,449,424 11/28/2023
Restricted 1,325,707,118 11/28/2023
Unrestricted 2,410,742,306 11/28/2023
Held at DTC 2,360,294,479 11/28/2023

Updated SS waited until a day after the 10Q to relay what was known 11 days prior to
Authorized Shares 5,500,000,000 11/03/2023
Outstanding Shares 3,736,449,424 11/03/2023
Restricted 1,325,707,118 11/03/2023
Unrestricted 2,410,742,306 11/03/2023Authorized Shares 5,500,000,000 10/27/2023
Outstanding Shares 3,736,449,424 10/27/2023
Restricted 1,325,707,118 10/27/2023
Unrestricted 2,410,742,306 10/27/2023
Held at DTC 2,284,545,036 10/27/2023
Held at DTC 2,202,010,410 09/29/2023 >24,149,625
YTD/DTC 643,685,499 + 82,534,626 = 726,220,125 divided by 10 months = 72,622,012.5 discounted shares p/m


Authorized Shares 4,500,000,000 09/29/2023
Outstanding Shares 3,450,665,355 09/29/2023
Restricted 1,198,207,118 09/29/2023
Unrestricted 2,252,458,237 09/29/2023
Held at DTC 2,202,010,410 09/29/2023 >24,149,625
YTD/DTC 643,685,499
643,685,499 divided by 9 (months) = 71,520,611 discounted shares monthly

SS for comparison then to now w/ the in between prior2 wink @ the bottom

Authorized Shares 3,500,000,000 6/1/20
Outstanding Shares 1,879,692,516 6/16/20
Restricted 1,352,226,123 6/12/20
Unrestricted 517,466,393 6/12/20
Held at DTC 484,713,398 6/15/20

Authorized Shares 4,500,000,000 09/15/2023
Outstanding Shares 3,364,758,336 09/15/2023
Restricted 1,136,449,724 09/15/2023
Unrestricted 2,228,308,612 09/15/2023
Held at DTC 2,177,860,785 09/15/2023
--------------------------------------------------------------------------------------------------------------------------------------------------------------------
Just the Facts TSOI SECURITY DETAILS Share Structure 12/17-03/04/21
Market Cap Market Cap 51,734,134 12/17/2021
Authorized Shares 3,500,000,000 12/17/2021
Outstanding Shares 2,311,123,860 12/17/2021 >16,927,248
Restricted 1,014,553,256 12/17/2021 >10,000,000
Unrestricted 1,296,570,604 12/17/2021 >6,927,248
Held at DTC 1,252,872,777 12/17/2021 >7,927,248

TSOI 11/15/21 Authorized Shares 3,500,000,000 1/15/2021
Outstanding Shares 2,294,196,612 11/15/2021
Restricted 1,004,553,256 11/15/2021
Unrestricted 1,289,643,356 11/15/2021
Held at DTC 1,244,945,529 11/15/2021

Share Structure Update 10/18/21
Market Cap Market Cap 87,926,139 10/21/2021
Authorized Shares 3,500,000,000 10/18/2021
Outstanding Shares 2,274,932,452 10/18/2021
Restricted 990,553,256 10/18/2021
Unrestricted 1,284,379,196 10/18/2021
Held at DTC 1,240,681,369 10/18/2021

O/S NO change
Restricted NO change
Unrestricted NO change
Held @ DTC >5m

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166066740
Authorized Shares 3,500,000,000 09/23/21
Updated O/S 2,274,135,577 09/23/21
Restricted 989,756,381 09/23/21
Unrestricted 1,284,379,196 09/23/21
Held at DTC 1,235,681,369 09/23/21

https://www.otcmarkets.com/stock/TSOI/security

as of 09/08/2021 $TSOI SECURITY DETAILS Share Structure
Market Cap Market Cap 177,382,575 09/15/2021
Authorized Shares3,500,000,000 09/08/2021
Outstanding Shares 2,274,135,577 09/08/2021
Restricted 1,094,756,381 09/08/2021
Unrestricted 1,179,379,196 09/08/2021
Held at DTC 1,129,681,369 09/08/2021

Share Structure 8/25/21
Market Cap Market Cap 201,463,566 08/31/2021
Authorized Shares 3,500,000,000 08/25/2021
Outstanding Shares 2,273,135,577 08/25/2021
Restricted 1,100,756,381 08/25/2021
Unrestricted 1,172,379,196 08/25/2021
Held at DTC 1,129,681,369 08/25/2021

TSOI Updated SS 9/01/21 http://investorshub.advfn.com/uimage/uploads/2021/9/1/jofddScreenshot_2021-09-01_174143.png

TSOI Share Structure
Market Cap Market Cap 138,081,770 08/11/2021
Authorized Shares 3,500,000,000 08/03/2021
Outstanding Shares 2,263,635,577 08/03/2021
Restricted 1,093,801,208 08/03/2021
Unrestricted 1,169,834,369 08/03/2021
Held at DTC 1,129,681,369 08/03/2021

TSOI Share Structure
Market Cap Market Cap 77,985,701 07/27/2021
Authorized Shares 3,500,000,000 7/09/2021
Outstanding Shares 2,259,800,077 07/09/2021
Restricted 1,092,501,208 07/09/2021
Unrestricted 1,167,298,869 07/09/2021
Held at DTC 1,119,045,869 07/09/2021
Float 303,593,877 08/16/20

7/9/21 TSOI SECURITY DETAILS
Share Structure
Market Cap 74,563,501 07/08/2021
Authorized Shares 3,500,000,000 06/02/2021
Outstanding Shares 2,252,673,740 06/02/2021
Restricted 1,088,601,692 06/02/2021
Unrestricted 1,164,072,048 06/02/2021
Held at DTC 1,092,456,980 06/02/2021
Float 303,593,877 08/16/2019
Par Value 0.001

TSOI SECURITY DETAILS 5/19/21
Share Structure
Market Cap Market Cap 116,553,339 05/25/2021
Authorized Shares 3,500,000,000 05/19/2021
Outstanding Shares 2,252,673,740 05/19/2021
Restricted 1,107,101,692 05/19/2021
Unrestricted 1,145,572,048 05/19/2021
Held at DTC 1,075,956,980 05/19/2021
Float 303,593,877 08/16/2019

TSOI SECURITY DETAILS
Share Structure
Market Cap 148,566,113 05/10/2021
Authorized Shares 3,500,000,000 05/04/2021
Outstanding Shares 2,251,001,716 05/04/2021
Restricted 1,107,101,692 05/04/2021
Unrestricted 1,143,900,024 n05/04/2021
Held at DTC 1,050,534,956 05/04/2021
Float 303,593,877 08/16/2019

Share Structure
Market Cap Market Cap 173,270,990 03/12/2021
Authorized Shares 3,500,000,000 03/04/2021
Outstanding Shares 2,243,571,019 03/04/2021
Restricted 1,279,963,335 03/04/2021
Unrestricted 963,607,684 03/04/2021
Held at DTC 805,734,684 03/04/2021

TSOI.... Authorized Sharesn 3,500,000,000
Outstanding Shares 2,243,571,019 03/04/2021
Restricted 1,279,963,335 03/04/2021
Unrestricted 963,607,684 03/04/2021
Held at DTC 805,734,684 03/04/2021
Float 303,593,877 03/04/202
Unrestricted 1,296,570,604 12/17/2021 >6,927,248
Held at DTC 1,252,872,777 12/17/2021 >7,927,248

TSOI 11/15/21 Authorized Shares 3,500,000,000 1/15/2021
Outstanding Shares 2,294,196,612 11/15/2021
Restricted 1,004,553,256 11/15/2021
Unrestricted 1,289,643,356 11/15/2021
Held at DTC 1,244,945,529 11/15/2021

Share Structure Update 10/18/21
Market Cap Market Cap 87,926,139 10/21/2021
Authorized Shares 3,500,000,000 10/18/2021
Outstanding Shares 2,274,932,452 10/18/2021
Restricted 990,553,256 10/18/2021
Unrestricted 1,284,379,196 10/18/2021
Held at DTC 1,240,681,369 10/18/2021

O/S NO change
Restricted NO change
Unrestricted NO change
Held @ DTC >5m

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166066740
Authorized Shares 3,500,000,000 09/23/21
Updated O/S 2,274,135,577 09/23/21
Restricted 989,756,381 09/23/21
Unrestricted 1,284,379,196 09/23/21
Held at DTC 1,235,681,369 09/23/21

https://www.otcmarkets.com/stock/TSOI/security

as of 09/08/2021 $TSOI SECURITY DETAILS Share Structure
Market Cap Market Cap 177,382,575 09/15/2021
Authorized Shares3,500,000,000 09/08/2021
Outstanding Shares 2,274,135,577 09/08/2021
Restricted 1,094,756,381 09/08/2021
Unrestricted 1,179,379,196 09/08/2021
Held at DTC 1,129,681,369 09/08/2021

Share Structure 8/25/21
Market Cap Market Cap 201,463,566 08/31/2021
Authorized Shares 3,500,000,000 08/25/2021
Outstanding Shares 2,273,135,577 08/25/2021
Restricted 1,100,756,381 08/25/2021
Unrestricted 1,172,379,196 08/25/2021
Held at DTC 1,129,681,369 08/25/2021

TSOI Updated SS 9/01/21 http://investorshub.advfn.com/uimage/uploads/2021/9/1/jofddScreenshot_2021-09-01_174143.png

TSOI Share Structure
Market Cap Market Cap 138,081,770 08/11/2021
Authorized Shares 3,500,000,000 08/03/2021
Outstanding Shares 2,263,635,577 08/03/2021
Restricted 1,093,801,208 08/03/2021
Unrestricted 1,169,834,369 08/03/2021
Held at DTC 1,129,681,369 08/03/2021

TSOI Share Structure
Market Cap Market Cap 77,985,701 07/27/2021
Authorized Shares 3,500,000,000 7/09/2021
Outstanding Shares 2,259,800,077 07/09/2021
Restricted 1,092,501,208 07/09/2021
Unrestricted 1,167,298,869 07/09/2021
Held at DTC 1,119,045,869 07/09/2021
Float 303,593,877 08/16/20

7/9/21 TSOI SECURITY DETAILS
Share Structure
Market Cap 74,563,501 07/08/2021
Authorized Shares 3,500,000,000 06/02/2021
Outstanding Shares 2,252,673,740 06/02/2021
Restricted 1,088,601,692 06/02/2021
Unrestricted 1,164,072,048 06/02/2021
Held at DTC 1,092,456,980 06/02/2021
Float 303,593,877 08/16/2019
Par Value 0.001

TSOI SECURITY DETAILS 5/19/21
Share Structure
Market Cap Market Cap 116,553,339 05/25/2021
Authorized Shares 3,500,000,000 05/19/2021
Outstanding Shares 2,252,673,740 05/19/2021
Restricted 1,107,101,692 05/19/2021
Unrestricted 1,145,572,048 05/19/2021
Held at DTC 1,075,956,980 05/19/2021
Float 303,593,877 08/16/2019

TSOI SECURITY DETAILS
Share Structure
Market Cap 148,566,113 05/10/2021
Authorized Shares 3,500,000,000 05/04/2021
Outstanding Shares 2,251,001,716 05/04/2021
Restricted 1,107,101,692 05/04/2021
Unrestricted 1,143,900,024 n05/04/2021
Held at DTC 1,050,534,956 05/04/2021
Float 303,593,877 08/16/2019

Share Structure
Market Cap Market Cap 173,270,990 03/12/2021
Authorized Shares 3,500,000,000 03/04/2021
Outstanding Shares 2,243,571,019 03/04/2021
Restricted 1,279,963,335 03/04/2021
Unrestricted 963,607,684 03/04/2021
Held at DTC 805,734,684 03/04/2021

TSOI.... Authorized Sharesn 3,500,000,000
Outstanding Shares 2,243,571,019 03/04/2021
Restricted 1,279,963,335 03/04/2021
Unrestricted 963,607,684 03/04/2021
Held at DTC 805,734,684 03/04/2021
Float 303,593,877 03/04/2021

Accumulated deficit (18,812,339 )

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Date: August 21, 2023

By: /s/ Timothy G. Dixon
Timothy G. Dixon
President and Chief Executive Officer
(Principal Executive Officer)

TSOI 11/15/21 Authorized Shares 3,500,000,000 1/15/2021
Outstanding Shares 2,294,196,612 11/15/2021
Restricted 1,004,553,256 11/15/2021
Unrestricted 1,289,643,356 11/15/2021
Held at DTC 1,244,945,529 11/15/2021

Share Structure Update 10/18/21
Market Cap Market Cap 87,926,139 10/21/2021
Authorized Shares 3,500,000,000 10/18/2021
Outstanding Shares 2,274,932,452 10/18/2021
Restricted 990,553,256 10/18/2021
Unrestricted 1,284,379,196 10/18/2021
Held at DTC 1,240,681,369 10/18/2021

O/S NO change
Restricted NO change
Unrestricted NO change
Held @ DTC >5m

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166066740
Authorized Shares 3,500,000,000 09/23/21
Updated O/S 2,274,135,577 09/23/21
Restricted 989,756,381 09/23/21
Unrestricted 1,284,379,196 09/23/21
Held at DTC 1,235,681,369 09/23/21

https://www.otcmarkets.com/stock/TSOI/security

as of 09/08/2021 $TSOI SECURITY DETAILS Share Structure
Market Cap Market Cap 177,382,575 09/15/2021
Authorized Shares3,500,000,000 09/08/2021
Outstanding Shares 2,274,135,577 09/08/2021
Restricted 1,094,756,381 09/08/2021
Unrestricted 1,179,379,196 09/08/2021
Held at DTC 1,129,681,369 09/08/2021

Share Structure 8/25/21
Market Cap Market Cap 201,463,566 08/31/2021
Authorized Shares 3,500,000,000 08/25/2021
Outstanding Shares 2,273,135,577 08/25/2021
Restricted 1,100,756,381 08/25/2021
Unrestricted 1,172,379,196 08/25/2021
Held at DTC 1,129,681,369 08/25/2021

TSOI Updated SS 9/01/21 http://investorshub.advfn.com/uimage/uploads/2021/9/1/jofddScreenshot_2021-09-01_174143.png

TSOI Share Structure
Market Cap Market Cap 138,081,770 08/11/2021
Authorized Shares 3,500,000,000 08/03/2021
Outstanding Shares 2,263,635,577 08/03/2021
Restricted 1,093,801,208 08/03/2021
Unrestricted 1,169,834,369 08/03/2021
Held at DTC 1,129,681,369 08/03/2021

TSOI Share Structure
Market Cap Market Cap 77,985,701 07/27/2021
Authorized Shares 3,500,000,000 7/09/2021
Outstanding Shares 2,259,800,077 07/09/2021
Restricted 1,092,501,208 07/09/2021
Unrestricted 1,167,298,869 07/09/2021
Held at DTC 1,119,045,869 07/09/2021
Float 303,593,877 08/16/20

7/9/21 TSOI SECURITY DETAILS
Share Structure
Market Cap 74,563,501 07/08/2021
Authorized Shares 3,500,000,000 06/02/2021
Outstanding Shares 2,252,673,740 06/02/2021
Restricted 1,088,601,692 06/02/2021
Unrestricted 1,164,072,048 06/02/2021
Held at DTC 1,092,456,980 06/02/2021
Float 303,593,877 08/16/2019
Par Value 0.001

TSOI SECURITY DETAILS 5/19/21
Share Structure
Market Cap Market Cap 116,553,339 05/25/2021
Authorized Shares 3,500,000,000 05/19/2021
Outstanding Shares 2,252,673,740 05/19/2021
Restricted 1,107,101,692 05/19/2021
Unrestricted 1,145,572,048 05/19/2021
Held at DTC 1,075,956,980 05/19/2021
Float 303,593,877 08/16/2019

TSOI SECURITY DETAILS
Share Structure
Market Cap 148,566,113 05/10/2021
Authorized Shares 3,500,000,000 05/04/2021
Outstanding Shares 2,251,001,716 05/04/2021
Restricted 1,107,101,692 05/04/2021
Unrestricted 1,143,900,024 n05/04/2021
Held at DTC 1,050,534,956 05/04/2021
Float 303,593,877 08/16/2019

Share Structure
Market Cap Market Cap 173,270,990 03/12/2021
Authorized Shares 3,500,000,000 03/04/2021
Outstanding Shares 2,243,571,019 03/04/2021
Restricted 1,279,963,335 03/04/2021
Unrestricted 963,607,684 03/04/2021
Held at DTC 805,734,684 03/04/2021

TSOI.... Authorized Sharesn 3,500,000,000
Outstanding Shares 2,243,571,019 03/04/2021
Restricted 1,279,963,335 03/04/2021
Unrestricted 963,607,684 03/04/2021
Held at DTC 805,734,684 03/04/2021
Float 303,593,877 03/04/202
Unrestricted 1,296,570,604 12/17/2021 >6,927,248
Held at DTC 1,252,872,777 12/17/2021 >7,927,248

TSOI 11/15/21 Authorized Shares 3,500,000,000 1/15/2021
Outstanding Shares 2,294,196,612 11/15/2021
Restricted 1,004,553,256 11/15/2021
Unrestricted 1,289,643,356 11/15/2021
Held at DTC 1,244,945,529 11/15/2021

Share Structure Update 10/18/21
Market Cap Market Cap 87,926,139 10/21/2021
Authorized Shares 3,500,000,000 10/18/2021
Outstanding Shares 2,274,932,452 10/18/2021
Restricted 990,553,256 10/18/2021
Unrestricted 1,284,379,196 10/18/2021
Held at DTC 1,240,681,369 10/18/2021

O/S NO change
Restricted NO change
Unrestricted NO change
Held @ DTC >5m

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166066740
Authorized Shares 3,500,000,000 09/23/21
Updated O/S 2,274,135,577 09/23/21
Restricted 989,756,381 09/23/21
Unrestricted 1,284,379,196 09/23/21
Held at DTC 1,235,681,369 09/23/21

https://www.otcmarkets.com/stock/TSOI/security

as of 09/08/2021 $TSOI SECURITY DETAILS Share Structure
Market Cap Market Cap 177,382,575 09/15/2021
Authorized Shares3,500,000,000 09/08/2021
Outstanding Shares 2,274,135,577 09/08/2021
Restricted 1,094,756,381 09/08/2021
Unrestricted 1,179,379,196 09/08/2021
Held at DTC 1,129,681,369 09/08/2021

Share Structure 8/25/21
Market Cap Market Cap 201,463,566 08/31/2021
Authorized Shares 3,500,000,000 08/25/2021
Outstanding Shares 2,273,135,577 08/25/2021
Restricted 1,100,756,381 08/25/2021
Unrestricted 1,172,379,196 08/25/2021
Held at DTC 1,129,681,369 08/25/2021

TSOI Updated SS 9/01/21 http://investorshub.advfn.com/uimage/uploads/2021/9/1/jofddScreenshot_2021-09-01_174143.png

TSOI Share Structure
Market Cap Market Cap 138,081,770 08/11/2021
Authorized Shares 3,500,000,000 08/03/2021
Outstanding Shares 2,263,635,577 08/03/2021
Restricted 1,093,801,208 08/03/2021
Unrestricted 1,169,834,369 08/03/2021
Held at DTC 1,129,681,369 08/03/2021

TSOI Share Structure
Market Cap Market Cap 77,985,701 07/27/2021
Authorized Shares 3,500,000,000 7/09/2021
Outstanding Shares 2,259,800,077 07/09/2021
Restricted 1,092,501,208 07/09/2021
Unrestricted 1,167,298,869 07/09/2021
Held at DTC 1,119,045,869 07/09/2021
Float 303,593,877 08/16/20

7/9/21 TSOI SECURITY DETAILS
Share Structure
Market Cap 74,563,501 07/08/2021
Authorized Shares 3,500,000,000 06/02/2021
Outstanding Shares 2,252,673,740 06/02/2021
Restricted 1,088,601,692 06/02/2021
Unrestricted 1,164,072,048 06/02/2021
Held at DTC 1,092,456,980 06/02/2021
Float 303,593,877 08/16/2019
Par Value 0.001

TSOI SECURITY DETAILS 5/19/21
Share Structure
Market Cap Market Cap 116,553,339 05/25/2021
Authorized Shares 3,500,000,000 05/19/2021
Outstanding Shares 2,252,673,740 05/19/2021
Restricted 1,107,101,692 05/19/2021
Unrestricted 1,145,572,048 05/19/2021
Held at DTC 1,075,956,980 05/19/2021
Float 303,593,877 08/16/2019

TSOI SECURITY DETAILS
Share Structure
Market Cap 148,566,113 05/10/2021
Authorized Shares 3,500,000,000 05/04/2021
Outstanding Shares 2,251,001,716 05/04/2021
Restricted 1,107,101,692 05/04/2021
Unrestricted 1,143,900,024 n05/04/2021
Held at DTC 1,050,534,956 05/04/2021
Float 303,593,877 08/16/2019

Share Structure
Market Cap Market Cap 173,270,990 03/12/2021
Authorized Shares 3,500,000,000 03/04/2021
Outstanding Shares 2,243,571,019 03/04/2021
Restricted 1,279,963,335 03/04/2021
Unrestricted 963,607,684 03/04/2021
Held at DTC 805,734,684 03/04/2021

TSOI.... Authorized Sharesn 3,500,000,000
Outstanding Shares 2,243,571,019 03/04/2021
Restricted 1,279,963,335 03/04/2021
Unrestricted 963,607,684 03/04/2021
Held at DTC 805,734,684 03/04/2021
Float 303,593,877 03/04/2021

Officers (like the CEO) and members of the Board of Directors can absolutely still be sued personally—even after the company delists and goes private. Here's how it works:
Delisting Doesn’t Grant Immunity
Just because a company delists from a stock exchange or goes private doesn't shield its executives or board members from legal liability for actions taken while the company was public. Key points:

Securities fraud and breach of fiduciary duty claims typically relate to conduct that occurred while the company was public.

These claims remain valid even after the company goes private or delists.

Delisting might make it harder to monitor future misconduct, but past misconduct is still fully actionable.


They Be Sued Personally with Limits
You can sue individual directors and officers for things like:

Securities fraud (e.g., knowingly misleading shareholders)

Breach of fiduciary duty

Self-dealing or insider trading

Negligence or gross mismanagement


Going Private Doesn’t “Erase” Liability
Even if the company is taken private through a buyout (e.g., private equity), this does not erase previous misconduct or prevent lawsuits.

In fact, going private can sometimes trigger additional lawsuits—especially if:

The buyout undervalues the company (minority shareholders may sue for unfair treatment).

The deal is structured to shield insiders or hide prior fraud.

Red Flags That Strengthen Your Case
Officers issued themselves new shares while misleading investors

Press releases or filings overstated product potential, partnerships, or financial position


Officers sold shares before bad news was revealed...[color=red][/color]

Going private was timed to avoid further disclosure or lawsuits

Idaho properties bought as supposed company property yet only used as a mailing address or for personal use up & until going private would be a serious allegation — and if substantiated, it could be grounds for personal liability, civil fraud, and possibly even criminal charges against the CEO. 

Summary: This May Be Embezzlement, Fraud, or Breach of Fiduciary Duty
If the CEO used company funds (investor/shareholder capital) to buy personal vacation or retirement properties, that could constitute:

Misappropriation of corporate assets
Using corporate funds for personal use — without legitimate compensation or board approval — is a clear breach of fiduciary duty.

Self-dealing
Directing corporate funds for personal gain without disclosure or shareholder consent is illegal and unethical.

Fraud
If this spending was hidden, mischaracterized in financial statements, or not disclosed to investors, it may constitute securities fraud or wire fraud, depending on how the funds moved.

Possible criminal liability
This goes beyond civil liability. If you have proof (documents, emails, public records of real estate transactions, etc.), this could be referred to:

The SEC (for public companies)

The Department of Justice (for criminal fraud)

State Attorney General or Securities Regulator


What The Idaho Corporate Properties Likely Constitutes:
1. Corporate Embezzlement
The CEO has misused company funds for personal benefit. This is theft, not just mismanagement.

2. Breach of Fiduciary Duty
CEOs owe a duty of loyalty and care to shareholders. Using company funds for personal enrichment is a blatant breach.

3. Fraud and Misrepresentation
If the CEO concealed this behavior from shareholders, the SEC, or other stakeholders (or misrepresented it in filings), this is securities fraud—possibly wire fraud too.

4. Unjust Enrichment
Even if the company delists or goes private, this personal enrichment can be challenged and possibly reversed through civil lawsuits or asset recovery.


Impact of Company Going Private:
The CEO may believe that delisting means he escapes scrutiny. That’s false. If the misconduct occurred while the company was public or using investor money, it:

Remains fully actionable

Can be prosecuted or sued over regardless of public/private status

Could trigger personal liability and asset seizure

Courts can issue:

Civil judgments to return stolen funds or assets

Freezing orders or liens on misappropriated property

Criminal asset forfeiture, in extreme cases[/color]

What the statements relayed publicly from the CEO regarding the Idaho properties likely means legally:
The CEO’s explanation — that the properties were bought "to avoid California laws that were never implemented", but he personally uses the property in Idaho while the business remains operational and leased in California — adds multiple new legal issues:

The Above Points to Clear Fraud, Waste, and Self-Dealing
1. Pretextual Justification (False Business Purpose)
Claiming a business justification for purchasing real estate with company funds — then using it personally — is a fraudulent misuse of corporate assets.

The fact that the laws were never implemented and the business is still operating in California kills any credibility to the explanation.


2. Personal Use = Conversion of Corporate Property
If the Idaho property was purchased using company/investor funds but is being used personally for non-business purposes (e.g., trout fishing, leisure), this is potentially:

Conversion (civil theft)

Unjust enrichment

Breach of fiduciary duty

Possibly tax fraud if it was written off as a business expense


3. Waste of Corporate Assets
The CEO made an investment of company capital with no clear business value, and is enjoying personal benefits while shareholders carry the loss.

Courts can rule that this is corporate waste and order repayment or asset forfeiture.[/color]

You Now Have a Strong Civil and Possibly Criminal Case & your case would be strengthened by

A regulatory complaint to the SEC, CA Attorney General, or Idaho AG

 

 





 
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
New Post